Elon Musk’s company Neuralink announced Thursday that it received approval from the Food and Drug Administration (FDA) to conduct its first-in-human clinical study.
“We are excited to share that we have received the FDA’s approval to launch our first-in-human clinical study,” the company said i
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased